Clinical Trial Update: 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluated two doses of an approved Merck drug for a new indication to prevent postoperative nausea and vomiting; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postoperative Nausea and Vomiting

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Postoperative Nausea and Vomiting | Phase 3 | Status: COMPLETED